A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Subcutaneous Tarlatamab in Subjects With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

Amgen

Summary

The primary objective of this study is to evaluate the safety and tolerability of subcutaneous (SC) tarlatamab.

Eligibility

Age range: 18+ years
Sex: All
Healthy volunteers: No

Detailed criteria

Inclusion Criteria: * Participants ≥ 18 years of age (or ≥ legal adult age within country if it is older than 18 years) at time of signing informed consent. * Participants with histologically or cytologically confirmed ES-SCLC that progressed or recurred following at least one line of platinum-based anti-cancer therapy for SCLC. Note: Participants with prior treatment for LS-SCLC should have also received another regimen for their recurrent, ES-SCLC disease. * Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1. * Participants must have adequate organ function (cardi…

Locations (31)

University of Southern California, Norris Comprehensive Cancer Center
Los Angeles, California
University of Illinois Chicago
Chicago, Illinois
Trinity Health Saint Joseph Mercy Ann Arbor
Ann Arbor, Michigan
Avera Cancer Institute
Sioux Falls, South Dakota
University of Texas MD Anderson Cancer Center
Houston, Texas
Swedish Cancer Institute
Seattle, Washington

Summary

Eligibility

Interventions

Locations (31)